Drug intelligence / Profile preview

PDNO

Development stage: Phase 2
Lead developer: AttgeNO
Modality: Small Molecules
Administration: Inhalation

Overview

PDNO is a code name for a drug candidate known as organic mononitrites of 1,2-propanediol. It is an investigational compound being studied primarily as a nitric oxide (NO) donor. The mechanism of action involves the release of nitric oxide, which acts as a vasodilator by relaxing vascular smooth muscle and thereby increasing blood flow. PDNO has been investigated in preclinical and early clinical studies for its potential use in conditions such as pulmonary hypertension and acute respiratory distress syndrome (ARDS), where improved pulmonary vasodilation may be beneficial. The drug is not currently approved for any indication.

Other names: 1-(nitrosooxy)propan-2-ol2-(nitrosooxy)propan-1-ol

Targets

sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on PDNO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDNO.

Explore the full profile